- AsiDNA™ proven to overcome resistance to tyrosine kinase inhibitors in lung cancer models
- AsiDNA™ proven to protect healthy cells when combined with conventional antitumor treatments
Paris (France), March 31, 2022 – 6 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), today announced that it will present new preclinical data confirming AsiDNA™’s abilities to protect from anticancer treatment toxicity and fight tumor resistance during poster and oral sessions at the upcoming American Association for Cancer Research Annual Meeting (AACR Annual Meeting 2022, April 8-13, 2022).
The oral presentation will describe how AsiDNA™ efficiently prevented the emergence of resistances to tyrosine kinase inhibitors in several models of targetable oncogenic addiction and will point to the therapeutic opportunity of combining AsiDNA™ and TKI (tyrosine kinase inhibitors) to overcome resistance in a clinical setting. These data were obtained within the framework of the collaboration with Pr. Gilles Favre (Cancer Research Center of Toulouse).
The poster presentation supports AsiDNA™’s potential to protect healthy cells from toxicities of several anti-cancer treatments. When combined with different anti-cancer treatments (Carboplatin+/-Paclitaxel in long-term treatment, Radiotherapy, Doxorubicin, PARP inhibitors), AsiDNA™ induces its nuclear target engagement only in dividing cells, while preserving healthy non dividing cells. In addition, in certain proliferating healthy cells, AsiDNA™ induces a stop in their division or boosts their DNA repair activity, thus protecting them from the toxic effects of anti-cancer treatments. These data were obtained in in vivo and in vitro models within the framework of the collaboration with Pr. Marie Dutreix (Institut Curie).
Wael Jdey, Preclinical Lead of Onxeo, stated: “These new data accepted for presentation at the AACR 2022 complement the pre-clinical and clinical package already obtained with AsiDNA™. With its differentiated mechanism of action, AsiDNA™ has shown its ability to work in the new preclinical tumor models that are resistant to TKi’s especially Osimertinib in EGFR-mutated NSCLC models. We are excited to present these data to the scientific community and are looking forward to initiating the next steps of the AsiDNA™ development plan”.
Oral Session: MS.ET03.01 – Elucidating Disease Biology and Drug Resistance Mechanisms
Date/ Time: April 10, 2022 – 3:35 AM – 3:50 PM (U.S. Eastern Daylight Time – EDT)
To read the abstract: DNA repair-interfering molecule AsiDNA® overcomes resistance to tyrosine kinase inhibitors in lung cancer
Poster Session: PO.ET04.02 – DNA Damage Response and Repair
Date/ Time: April 12, 2022 – 9:00 AM – 12:30 PM (U.S. Eastern Daylight Time – EDT)
To read the abstract: AsiDNA® treatment protects healthy cells from anticancer treatment toxicity
